Kyle Lahucik is an Associate Editor at Biotech. He covers a range of topics within the healthcare sector, focusing on medicine and healthcare, alternative medicine, healthcare technology, and wellness, with a particular interest in biotech, startups, and market dynamics. Kyle's work has been featured in Bloomberg News and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kyle Lahucik's articles predominantly cover healthcare and pharmaceutical industry, with a strong focus on biotech, drug development, clinical trials, and biotech IPOs. His coverage heavily features press releases and private sector announcements.
Given his extensive reporting on the healthcare and pharmaceutical industry, Kyle would likely be interested in pitches that offer exclusive insights into new drug developments or clinical trial results. Additionally, he may also be open to receiving information about significant partnerships or acquisitions within the biotech and pharmaceutical sectors.
It seems that Kyle does not have a specific geographic focus but rather covers global developments in the healthcare and pharmaceutical industries. Therefore, pitches should center around events of international significance within these sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Roche's Chugai partners with Araris Biotech on multi-payload ADCs, as Swiss biotech advances tech allowing multiple cytotoxic molecules per antibody
Tenvie Therapeutics launches with $200M, acquires Denali drug candidates, led by Tony Estrada with NLRP3 and SARM1 inhibitors in IND-enabling stage.
By: Kyle Lahucik
There's a shopping bonanza for new obesity medicines going on among a marquee cohort of biopharma investors who are in-licensing treatment candidates from Chinese and European drug developers. Joining the ...
A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 million and acquired a nimble Singapore startup …
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie and others, plus a partnership with …
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting medicines, known simply as TCEs, are …
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about half a year after its
SAN FRANCISCO — Ben Auspitz, a veteran biotech investor and repeat entrepreneur, is reuniting with longtime collaborator Alexis Borisy and his “free the founders” …
By: Kyle Lahucik
Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun Yang aims for Nasdaq debut under AAPG ticker.
Bing Yao's ArriVent BioPharma has inked another licensing deal with a Chinese biopharma. The late-stage oncology biotech is picking up a new antibody-drug conjugate from …
(833) 317-6278 
